Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Cash from Investing Activities (2016 - 2019)

Alterity Therapeutics' quarterly Cash from Investing Activities came in at -$5123.2 in Q4 2019, down 118.19% year-on-year from $28162.0 in Q4 2018, and down 118.19% quarter-over-quarter from -$2348.0 in Q4 2018.

Alterity Therapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at -$5123.2 in Q4 2019.

  • For the quarter ending Q4 2019, Cash from Investing Activities fell 118.19% year-over-year to -$5123.2; the trailing twelve-month figure through Dec 2019 stood at -$26661.1 (changed N/A YoY), and the FY2025 full-year result was -$4.8 million, down 127275.44% from the prior year.
  • Cash from Investing Activities for Q4 2019 stood at -$5123.2, down from -$2348.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was -$2348.0 in Q4 2018, with the low at -$16622.8 in Q4 2016.
  • Average Cash from Investing Activities over 4 years is -$6665.3, with a median of -$3845.1 recorded in 2017.
  • Year-over-year, Cash from Investing Activities jumped 84.56% in 2017 and sank 118.19% in 2019.
  • Tracing ATHE's Cash from Investing Activities over 4 years: stood at -$16622.8 in 2016, then jumped by 84.56% to -$2567.1 in 2017, then advanced by 8.53% to -$2348.0 in 2018, then plunged by 118.19% to -$5123.2 in 2019.
  • The last three Cash from Investing Activities figures came in at -$5123.2 (Q4 2019), -$2348.0 (Q4 2018), and -$2567.1 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.89 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -25.54 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 172.62 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 -5,123.23
Dec 31, 2019 -5,123.23
Dec 31, 2018 -2,348.04
Dec 31, 2018 -2,348.04
Dec 31, 2017 -2,567.05
Dec 31, 2017 -2,567.05
Dec 31, 2016 -16,622.76
Dec 31, 2016 -16,622.76